Intracameral Injection of Methotrexate for Treatment of Epithelial Ingrowth

Farhad Salari; Ghasem Fakhraie; Fahimeh Asadi Amoli; Mehran Zarei-Ghanavati

doi:10.4103/JOCO.JOCO_159_21

Intracameral Injection of Methotrexate for Treatment of Epithelial Ingrowth

J Curr Ophthalmol. 2022 Apr 16;34(1):115-117. doi: 10.4103/JOCO.JOCO_159_21. eCollection 2022 Jan-Mar.

Authors

Farhad Salari¹, Ghasem Fakhraie¹, Fahimeh Asadi Amoli¹, Mehran Zarei-Ghanavati¹

Affiliation

¹ Department of Cornea, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Purpose: To report a case of intracameral injection of methotrexate (MTX) to treat the epithelial ingrowth that occurred following glaucoma surgery.

Methods: A case report of a 40-year-old male with epithelial ingrowth after implantation of Ahmed glaucoma valve.

Results: The patient was treated with 11 doses of weekly intracameral MTX (400 mg/0.1 ml). Clinical evidence of recurrence was not observed after 11 months of follow-up.

Discussion: Intracameral MTX can be used as an alternative for the treatment of epithelial ingrowth.

Keywords: Epithelial ingrowth; Glaucoma valve; Intracameral; Methotrexate.

Publication types

Case Reports